Sub-millimetric, patient-specific brain targeting for functional neurosurgery and real-world outcomes in Parkinson’s Disease and Essential Tremor.

FrenchWeb Highlights RebrAIn’s €3.7 Million Seed Funding for Parkinson’s Disease Innovation

We are thrilled to share that FrenchWeb has featured RebrAIn for securing €3.7 million in seed funding to advance our AI-driven solutions for treating Parkinson’s Disease.

Led by Karista and supported by Nouvelle Aquitaine Co-Investissement, this funding will accelerate the international expansion of our innovative platform, OptimDBS, which aims to simplify and standardize Deep Brain Stimulation procedures. This significant investment underscores our commitment to enhancing patient outcomes and making neurosurgical treatments more accessible.

Read the full story here (in French).

An English translation by Google is available here.

Our latest public updates

Rebrain publishes OPTIVIM trial results in Neurosurgery

Rebrain publishes OPTIVIM trial results in Neurosurgery

Dec 5, 2025

An innovative and automated method RebrAIn’s service is based on a machine learning model trained on data from successfully treated patients. Using only a standard 3D T1 MRI, the algorithm automatically computes the stereotactic coordinates of the optimal DBS target,...